Shares of Pfizer Inc. /zigman2/quotes/202877789/composite PFE +2.32% rallied 2.8% while Germany-based BioNTech SE /zigman2/quotes/214419716/composite BNTX +3.17% dropped 2.5% in premarket trading Tuesday, after the company said they submitted their COVID-19 vaccine candidate BNT162b2 for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA). If the EMA recommends granting a CMA, that could lead to use of BNT162b2 in Europe before the end of 2020. The companies had submitted BNT162b2 for Emergency Use Authorization to the Food and Drug Administration on Nov. 20. On Monday, Moderna Inc. /zigman2/quotes/205619834/composite MRNA +1.73% filed for EUA of its COVID-19 vaccine candidate, and said it will apply for CMA with the EMA. Shares of Pfizer have gained 9.7% over the past three months and BioNTech's stock has rocketed 114.9%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.84% has edged up 2.7%.